Bicocca Open Archive

Logo unimib boa
BIAGI, ETTORE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.975
AS - Asia 5.503
EU - Europa 4.512
SA - Sud America 758
AF - Africa 130
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 11
Totale 23.904
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.679
SG - Singapore 1.981
CN - Cina 1.273
HK - Hong Kong 747
SE - Svezia 720
RU - Federazione Russa 697
VN - Vietnam 676
DE - Germania 627
BR - Brasile 582
UA - Ucraina 494
IE - Irlanda 467
IT - Italia 467
GB - Regno Unito 298
CA - Canada 217
FR - Francia 209
IN - India 185
FI - Finlandia 143
BD - Bangladesh 102
TR - Turchia 87
KR - Corea 78
AR - Argentina 72
NL - Olanda 70
IQ - Iraq 58
MX - Messico 54
AT - Austria 53
ID - Indonesia 53
ES - Italia 51
BE - Belgio 46
PL - Polonia 46
PK - Pakistan 40
JP - Giappone 39
ZA - Sudafrica 39
DK - Danimarca 38
PH - Filippine 28
SA - Arabia Saudita 27
EC - Ecuador 23
BG - Bulgaria 22
VE - Venezuela 19
CO - Colombia 17
CL - Cile 16
UZ - Uzbekistan 16
TN - Tunisia 14
EG - Egitto 12
ET - Etiopia 11
IL - Israele 11
IR - Iran 11
MY - Malesia 11
RO - Romania 11
EU - Europa 10
MA - Marocco 10
NP - Nepal 10
BO - Bolivia 8
JM - Giamaica 8
JO - Giordania 8
KE - Kenya 8
UY - Uruguay 8
AE - Emirati Arabi Uniti 7
AU - Australia 7
CH - Svizzera 7
KZ - Kazakistan 7
AL - Albania 6
AZ - Azerbaigian 6
DZ - Algeria 6
NG - Nigeria 6
TH - Thailandia 6
BY - Bielorussia 5
CZ - Repubblica Ceca 5
MU - Mauritius 5
OM - Oman 5
PY - Paraguay 5
RS - Serbia 5
TW - Taiwan 5
AO - Angola 4
KG - Kirghizistan 4
LT - Lituania 4
MN - Mongolia 4
PA - Panama 4
PE - Perù 4
SN - Senegal 4
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HR - Croazia 3
NI - Nicaragua 3
NZ - Nuova Zelanda 3
PT - Portogallo 3
SK - Slovacchia (Repubblica Slovacca) 3
SY - Repubblica araba siriana 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BH - Bahrain 2
GA - Gabon 2
GR - Grecia 2
KW - Kuwait 2
LB - Libano 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
PS - Palestinian Territory 2
RW - Ruanda 2
SI - Slovenia 2
Totale 23.878
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.605
Woodbridge 1.238
Ashburn 1.228
Singapore 1.112
Fairfield 876
Houston 822
Hong Kong 734
Chandler 724
Wilmington 693
Jacksonville 518
Dublin 458
San Jose 442
Seattle 383
Frankfurt am Main 357
Cambridge 335
Dearborn 316
New York 238
Beijing 221
Princeton 194
Ho Chi Minh City 192
Santa Clara 180
Los Angeles 167
Chicago 156
Nanjing 135
Hanoi 134
Milan 130
Hefei 127
The Dalles 114
Shanghai 91
Dallas 87
Lawrence 85
Lachine 83
Lauterbourg 82
Altamura 68
Seoul 68
Council Bluffs 63
Buffalo 62
Moscow 61
Dong Ket 60
São Paulo 56
Vienna 49
San Diego 48
Helsinki 45
Brussels 44
Toronto 43
Orem 41
Boardman 39
Nanchang 38
Warsaw 37
Tianjin 35
London 34
Montreal 34
Andover 33
Guangzhou 33
Lissone 33
Da Nang 31
Shenyang 31
Fremont 30
Hebei 27
Denver 26
Mountain View 26
Rio de Janeiro 26
Stockholm 26
Hangzhou 25
Munich 25
Baghdad 24
Atlanta 23
Huizen 23
Tokyo 23
Amsterdam 22
Changsha 21
Zhengzhou 21
Brooklyn 20
Chennai 20
Plovdiv 20
Rome 20
Manchester 19
Poplar 19
Jakarta 18
Jinan 18
Ningbo 18
Ottawa 17
Salt Lake City 17
Boston 16
Haiphong 16
Jiaxing 16
Mexico City 16
Biên Hòa 14
Falls Church 14
Johannesburg 14
Kocaeli 14
Nürnberg 14
Philadelphia 14
San Francisco 14
Tashkent 14
Auburn Hills 13
Dhaka 13
Jeddah 13
Mumbai 13
Phoenix 13
Totale 16.158
Salva come PNG Salva come JPEG
Nome #
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 469
Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation 456
Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies 430
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 423
Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System 413
Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories 406
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 403
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133+ Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy 387
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 376
Balance of Anti-CD123 Chimeric Antigen Receptor Binding Affinity and Density for the Targeting of Acute Myeloid Leukemia 376
Mesenchymal stromal cells for the treatment of graft-versus-host disease: understanding the in vivo biological effect through patient immune monitoring 374
Interleukin-17-producing t-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation 353
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 344
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 341
Immunotherapy of acute leukemia by chimeric antigen receptormodified lymphocytes using an improved Sleeping Beauty transposon platform 338
T cells stimulated by CD40L positive leukemic blasts-pulsed dendritic cells meet optimal functional requirements for adoptive T-cell therapy 335
Stable Expression Of Chimeric Antigen Receptors (CARs) By Sleeping Beauty-Mediated Gene Transfer and Efficient Expansion Of Leukemia-Specific Cytokine-Induced Killer (CIK) Cells 333
Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population 327
Regulatory T cells and extracorporeal photochemotherapy: correlation with clinical response and decreased frequency of proinflammatory T cells. 326
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 324
Exploration of the lysis mechanisms of leukaemic blasts by chimaeric T-cells 307
Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation 306
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy 295
Characterization of Plated Lysate Cultured Mesenchymal Stromal Cells and Their Potential Use in Tissue-Engineered Osteogenic Devices for the Treatment of Bone Defects 294
Vaccination to improve the persistence of CD19CAR gene-modified T cells in relapsed pediatric acute lymphoblastic leukemia 293
Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives 283
Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors 283
Chimeric Antigen Receptors against CD33/CD123 antigens efficiently target primary Acute Myeloid Leukemia cells in vivo 283
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 282
Immunosuppression does not affect human bone marrow mesenchymal stromal cell efficacy after transplantation in traumatized mice brain 280
Chimeric T-cell receptors: New challenges for targeted immunotherapy in hematologic malignancies 279
Bath PUVA therapy in pediatric patients with drug-resistant cutaneous graft-versus-host disease 275
Extracorporeal photochemotherapy is accompanied by increasing levels of circulating CD4+CD25+GITR+Foxp3+CD62L+ functional regulatory T-cells in patients with graft-versus-host disease. 274
GMP-based CD133(+) cells isolation maintains progenitor angiogenic properties and enhances standardization in cardiovascular cell therapy 269
Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library 267
Donor-derived CD19-targeted T cells in allogeneic transplants 267
Polyomavirus JC-targeted T-cell therapy for progressive multiple leukoencephalopathy in a hematopoietic cell transplantation recipient 263
Upregulation of adhesion molecules on leukemia targets improves the efficacy of cytotoxic T cells transduced with chimeric anti-CD19 receptor 262
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor 261
Cytokine Induced Killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors 260
Targeting of Acute Myeloid Leukemia by Cytokine-Induced Killer Cells Redirected with a Novel CD123-Specific Chimeric Antigen Receptor 257
A life-threatening paediatric case of acute autoimmune haemolytic anaemia (AIHA) successfully cured by plasma-exchange and combined immunosuppressive treatment 254
Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells 251
Long-term effects of bone marrow transplantation on dental status in children with leukaemia 251
Failure of interferon-γ pre-treated mesenchymal stem cell treatment in a patient with crohn's disease 249
Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia 248
Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia 248
Isolation of monocytes from leukapheretic products for large-scale GMP-grade generation of cytomegalovirus-specific T-cell lines by means of an automated elutriation device 246
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes 245
TBI, etoposide and cyclophosphamide as a promising conditioning regimen for BMT in childhood ALL in second remission 245
Allogeneic mesenchymal stem cell infusion for the stabilization of focal segmental glomerulosclerosis 243
Development of an alveolar bone regeneration protocol with mesenchyl stem cells for the therapy of severe bone resorption in periodontal disease 242
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccine 238
Cell-based strategies to manage leukemia relapse: Efficacy and feasibility of immunotherapy approaches 238
T lymphocytes redirected against the κ light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells 237
Antigen-induced regulatory T cells 235
The washouts of discarded bone marrow collection bags and filters are a very abundant source of hMSCs 235
CD40 activation of BCP-ALL cells generates 11L-10-producing, 11L-12-defective APCs that induce allogeneic T-cell anergy 232
Febrile complications in the first 100 days after bone marrow transplantation in children: a single center's experience 230
Estudio experimental sobre la utilización de células madre humanas en la terapia de los defectos periodontales: resultados preliminares 222
Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia 222
Induction of antigen-specific regulatory T cells following overexpression of a Notch ligand by human B lymphocytes 217
Bystander transfer of functional human CD40 ligand from gene-modified fibroblasts to B-chronic lymphocytic leukemia cells 216
Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia 216
Role of early diagnosis for a noninvasive treatment of pulmonary thromboembolism in leukemic children 213
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation. 212
Chimeric Antigen Receptor for Specific Targeting of Acute Myeloid Leukemia 210
Intrathecal chemotherapy with antineoplastic agents in children 208
PTX3 as a potential novel tool for the diagnosis and monitoring of pulmonary fungal infections in immuno-compromised pediatric patients. 207
Overexpression of the Notch ligand, Jagged-1, induces alloantigen-specific human regulatory T cells 203
Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells 201
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis 200
Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression. Mol Cancer 196
Mechanical and infective central venous catheter-related complications: a prospective non-randomized study using Hickman and Groshong catheters in children with hematological malignancies 194
Prolonged extracorporeal membrane oxygenation therapy for severe acute respiratory distress syndrome in a child affected by rituximab-resistant autoimmune hemolytic anemia: A case report 192
A persistent severe autoimmune hemolytic anemia despite apparent direct antiglobulin test negativization 190
In Vitro and In Vivo Antitumor Effect of Anti-CD33 Chimeric Receptor-Expressing EBV-CTL against CD33 Acute Myeloid Leukemia 187
CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-gamma production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia 187
From Bone Marrow Transplantation to Cellular Therapies: Possible therapeutic strategies in managing autoimmune disorders 182
New advances in leukaemia immunotherapy by the use of Chimeric Artificial Antigen Receptors (CARs): state of the art and perspectives for the near future 179
Basic biology and clinical application of multipotent mesenchymal stromal cells: from bench to bedside 179
New findings about the Interplay among Clarithromycin, Immune and Central Nervous Systems 179
A Phase 1/2 Study of Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 in Patients With High-risk Neuroblastoma 177
In Vitro Comparison of Three Different Chimeric Receptor-modified Effector T-cell Populations for Leukemia Cell Therapy 176
Effectiveness of extracorporeal photochemotherapy in treating long-term refractory chronic graft-versus-host disease 173
LONG TERM SURVIVAL AND EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT DEPENDENT ON IMMUNOSUPPRESSIVE TREATMENT. 170
Low-Dose Lenalidomide Improves CAR-Based Immunotherapy In CLL By Reverting T-Cell Defects In Vivo 168
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor 159
Phase I Trial of Vaccination With Autologous Neuroblastoma Tumor Cells Genetically Modified to Secrete IL-2 and Lymphotactin 159
Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells 158
Mesenchymal stem/stromal cells: a new "cells as drugs" paradigm. Efficacy and critical aspects in cell therapy 149
Long term efficacy of human bone marrow mesenchymal stem cells in traumatized mice brain is not affected by immunosuppressive treatment 146
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 130
LONG TERM EFFICACY OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS IN TRAUMATIZED MICE BRAIN IS NOT AFFECTED BY IMMUNOSUPPRESSIVE TREATMENT. 120
null 78
Totale 24.316
Salva come PNG Salva come JPEG
Categoria #
all - tutte 73.656
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.656
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021280 0 0 0 0 0 0 0 0 0 0 85 195
2021/20221.376 51 135 208 106 71 68 58 66 138 134 98 243
2022/20232.370 271 739 198 224 136 355 24 151 171 6 69 26
2023/20241.359 46 39 61 56 202 348 264 62 112 8 30 131
2024/20252.976 185 333 135 141 255 74 140 116 385 477 239 496
2025/20266.895 797 467 510 860 1.018 452 973 394 712 692 20 0
Totale 24.316